The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis
Open accessAbstract
Background and Aims: Despite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis. Approach and Results: This retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy‐based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short‐term all‐cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long‐term all‐cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96). Conclusions: Most Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6‐month follow‐up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence‐based AUD treatments to patients with coexisting AUD and cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Self-citationReus, V. I., Fochtmann, L. J., Bukstein, O., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Mahoney, J., Pasic, J., Weaver, M., Wills, C. D., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.1750101 · Cited by 372 · cited 4×
“The American Psychiatric Association reported that less than 10% of all patients receive any treatment after an AUD diagnosis.(22,23) Even fewer receive evidence-based AUD treatments.”
BackgroundInfluentialDisulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347 · cited 1×
“Disulfiram inhibits acetaldehyde dehydrogenase, causing gastrointestinal symptoms, headache, and hypotension, when consumed with alcohol.(44) The potential for severe liver toxicity, hypotension, and psychiatric side effects may limit the use of disulfiram in patients with cirrhosis.”
BackgroundBarriers to alcoholism treatment: reasons for not seeking treatment in a general population sample.
Grant, B. F. (1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.365 · Cited by 334
Ho, S. B., Bräu, N., Cheung, R., Liu, L., Sanchez, C., Sklar, M., Phelps, T. E., Marcus, S. G., Wasil, M. M., Tisi, A., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.02.022 · Cited by 118
Pharmacotherapy for alcoholic patients with alcoholic liver disease
Vuittonet, C. L., Halse, M., Leggio, L., Fricchione, S. B., Brickley, M., Haass-Koffler, C. L., Tavares, T., Swift, R. M., & Kenna, G. A. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140028 · Cited by 51
Cited by
Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review
Singal, A. K., & Mathurin, P. (2021) · JAMA · doi:10.1001/jama.2021.7683 · Cited by 398
Diagnosis and Management of Cirrhosis and Its Complications: A Review
Tapper, E. B., & Parikh, N. D. (2023) · JAMA · doi:10.1001/jama.2023.5997 · Cited by 392
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002572 · Cited by 292
Self-citationBataller, R., Arab, J. P., & Shah, V. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2207599 · Cited by 259
Self-citationDanpanichkul, P., Díaz, L. A., Suparan, K., Tothanarungroj, P., Sirimangklanurak, S., Auttapracha, T., Blaney, H. L., Sukphutanan, B., Pang, Y., Kongarin, S., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0835 · Cited by 85
“14 Also, difficulties in hepatocellular carcinoma (HCC) surveillance have been identified in ALD.”
Management of alcohol use disorder in patients with chronic liver disease
Mellinger, J. L., Fernandez, A. C., & Winder, G. S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000145 · Cited by 52
“[41] For the shorter AUDIT-C, values of 3 or more in women and 4 or more in men are considered positive and suggestive of heavy drinking and need for intervention, while, for the 10-question AUDIT, values of 8–14 suggest hazardous or harmful consumption and values of 15 or more may suggest a moderate to severe AUD.”
BackgroundInfluentialVannier, A. G. L., Przybyszewski, E. M., Shay, J., Patel, S. J., Schaefer, E., Goodman, R. P., & Luther, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.001 · Cited by 38
Danpanichkul, P., Suparan, K., Ng, C. H., Dejvajara, D., Kongarin, S., Panpradist, N., Chaiyakunapruk, N., Muthiah, M. D., Chen, V. L., Huang, D. Q., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101020 · Cited by 37
“55 Essentially, there is a shortage of treatments for AUD and ALD, unlike for MASLD, another common cause of chronic liver disease.”
Gopalakrishna, H., Ghabril, M., Gu, J., Li, Y. J., Fontana, R. J., Kleiner, D. E., Koh, C., Chalasani, N., & for the Drug-Induced Liver Injury Network (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001421 · Cited by 12
Metadata
- Authors
- Rogal, S., Youk, A., Zhang, H., Gellad, W. F., Fine, M. J., Good, C. B., Chartier, M., DiMartini, A., Morgan, T., Bataller, R., & Kraemer, K. L.
- Venue
- Hepatology
- Published
- 2020-05-22
- Volume
- 71
- Issue
- 6
- Pages
- 2080-2092
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2991209261
- Cited by
- 218
- References
- 8
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.